June 13, 2017

June 12, 2017

Subscribe to Latest Legal News and Analysis

The Future Impact of Populism on Drug Pricing Reform

In 2016, the populist trend in American politics was an undeniable factor behind Trump’s election victory as well as the ascendancy of Bernie Sanders and Elizabeth Warren within the Democratic Party.  During upcoming months, industry observers will be looking for signs as to whether drug pricing is an area in which both parties can agree on instituting significant legislative action at the state and federal levels.  The nature and shape of any such reforms will be highly consequential for the U.S. pharmaceutical industry, which has served as a prime source of innovation in medicine.  The question going forward is whether cool-headed reform that facilitates patient access to drugs without stymying pharmaceutical R&D investment can be achieved in an era of fervent populism and discontent over rising healthcare costs.

©2017 Epstein Becker & Green, P.C. All rights reserved.

TRENDING LEGAL ANALYSIS


About this Author

John S. Linehan, Epstein Becker Green, Health Care Attorney, Life Science
Associate

JOHN “JACK” S. LINEHAN is an Associate in the Health Care and Life Sciences practice, in the Baltimore and Washington, DC, offices of Epstein Becker Green. His practice is primarily focused on pharmacy law, managed care, government investigations, and health care fraud and abuse matters.

443-663-1355